Korean scientists facilitates development of DNA-based medicine

Viromed Co. says it administered VM202RY, DNA-based medicine for ischemic disease including peripheral and coronary artery disease, to the last patient in the phase I, dose-escalation study for 9 Korean patients.

This trial has been conducted in Seoul National University Hospital in collaboration with Reyon Pharmaceutical. In the US, the phase I, dose-escalation study has been carried out in...